ERBB2 and breast cancer: Although there was no risk reduction benefit of statins on the ER- and HER2+ invasive cancers in the first 6 years, the risk of recurrence in both these ER- and HER2+ groups decreased significantly beyond the sixth year of diagnosis (HR 0.66, p=0.007 and HR 0.10, p=0.002 respectively).There was also an overall risk reduction benefit of statin in HER2- breast cancers, HR 0.74, p=0.026.